146 related articles for article (PubMed ID: 20852006)
1. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
Brainard DM; Kassahun K; Wenning LA; Petry AS; Liu C; Lunceford J; Hariparsad N; Eisenhandler R; Norcross A; DeNoia EP; Stone JA; Wagner JA; Iwamoto M
J Clin Pharmacol; 2011 Jun; 51(6):943-50. PubMed ID: 20852006
[TBL] [Abstract][Full Text] [Related]
2. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
3. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Breidinger SA; Mangin EC; Azrolan N; Greenberg HE; Haazen W; Stone JA; Gottesdiener KM; Wagner JA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4338-43. PubMed ID: 18838589
[TBL] [Abstract][Full Text] [Related]
4. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.
Wenning LA; Petry AS; Kost JT; Jin B; Breidinger SA; DeLepeleire I; Carlini EJ; Young S; Rushmore T; Wagner F; Lunde NM; Bieberdorf F; Greenberg H; Stone JA; Wagner JA; Iwamoto M
Clin Pharmacol Ther; 2009 Jun; 85(6):623-7. PubMed ID: 19279563
[TBL] [Abstract][Full Text] [Related]
6. The effect of raltegravir on the glucuronidation of lamotrigine.
van Luin M; Colbers A; Verwey-van Wissen CP; van Ewijk-Beneken-Kolmer EW; van der Kolk M; Hoitsma A; da Silva HG; Burger DM
J Clin Pharmacol; 2009 Oct; 49(10):1220-7. PubMed ID: 19717722
[TBL] [Abstract][Full Text] [Related]
7. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
Wenning LA; Hanley WD; Brainard DM; Petry AS; Ghosh K; Jin B; Mangin E; Marbury TC; Berg JK; Chodakewitz JA; Stone JA; Gottesdiener KM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2009 Jul; 53(7):2852-6. PubMed ID: 19433563
[TBL] [Abstract][Full Text] [Related]
8. Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
[TBL] [Abstract][Full Text] [Related]
9. Effect of raltegravir on the pharmacokinetics of methadone.
Anderson MS; Mabalot Luk JA; Hanley WD; Jin B; Riesenberg RA; Wenning LA; Chodakewitz JA; Wagner JA; Iwamoto M
J Clin Pharmacol; 2010 Dec; 50(12):1461-6. PubMed ID: 20173085
[TBL] [Abstract][Full Text] [Related]
10. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C
Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.
Dooley KE; Sayre P; Borland J; Purdy E; Chen S; Song I; Peppercorn A; Everts S; Piscitelli S; Flexner C
J Acquir Immune Defic Syndr; 2013 Jan; 62(1):21-7. PubMed ID: 23075918
[TBL] [Abstract][Full Text] [Related]
12. Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.
Vourvahis M; Davis J; Wang R; Layton G; Choo HW; Chong CL; Tawadrous M
Antimicrob Agents Chemother; 2012 Aug; 56(8):4303-9. PubMed ID: 22644026
[TBL] [Abstract][Full Text] [Related]
13. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
Iwamoto M; Hanley WD; Petry AS; Friedman EJ; Kost JT; Breidinger SA; Lasseter KC; Robson R; Lunde NM; Wenning LA; Stone JA; Wagner JA
Antimicrob Agents Chemother; 2009 May; 53(5):1747-52. PubMed ID: 19223645
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
Hamzeh FM; Benson C; Gerber J; Currier J; McCrea J; Deutsch P; Ruan P; Wu H; Lee J; Flexner C;
Clin Pharmacol Ther; 2003 Mar; 73(3):159-69. PubMed ID: 12621381
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.
Brainard DM; Wenning LA; Stone JA; Wagner JA; Iwamoto M
J Clin Pharmacol; 2011 Oct; 51(10):1376-402. PubMed ID: 21209233
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
17. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.
Iwamoto M; Kost JT; Mistry GC; Wenning LA; Breidinger SA; Marbury TC; Stone JA; Gottesdiener KM; Bloomfield DM; Wagner JA
J Clin Pharmacol; 2008 Jun; 48(6):726-33. PubMed ID: 18441333
[TBL] [Abstract][Full Text] [Related]
19. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.
Siccardi M; DʼAvolio A; Rodriguez-Novoa S; Cuenca L; Simiele M; Baietto L; Calcagno A; Moss D; Bonora S; Soriano V; Back DJ; Owen A; Di Perri G
Ther Drug Monit; 2012 Apr; 34(2):232-5. PubMed ID: 22406652
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
